Association Between Administration of Dexmedetomidine and Postoperative Mortality in Hospitals

NCT06248346 | Completed

• 1 other identifier: KY20192045-C-1
• Study Type: observational
• Target: 518,043
• Locations: 0 countries
• Sites: N/A

Brief Summary

The present multicentre retrospective cohort study aimed to investigate the association between intraoperative administration of dexmedetomidine and postoperative mortality in hospitals. The investigators set out to test the hypothesis that perioperative dexmedetomidine use, as an adjunct to general anesthesia, diminishes postoperative mortality in hospitals across all categories of surgical patients.

Conditions

In-hospital Mortality

Outcome Measures

Primary Outcomes (1)

• in-hospital all-cause mortality

  in-hospital deaths or discharged to hospice (or home)

  from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 1 year

Secondary Outcomes (3)

• length of postoperative hospital stay

  from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 1 year

• admission to the intensive care unit (ICU)

  from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 1 year

• adverse events after surgery

  from the time of end of surgery until time of documented hospital discharge or time of death, whichever came first, assessed up to 1 year

Study Arms (2)

dexmedetomidine

dexmedetomidine group: abbreviated for dexmedetomidine group, refers to the group with intraoperative administration of dexmedetomidine adjunct to propofol

Drug: Dexmedetomidine

non-dexmedetomidine

non-dexmedetomidine group: abbreviated for non-dexmedetomidine group, refers to the group without intraoperative administration of dexmedetomidine adjunct to propofol

Interventions

Dexmedetomidine DRUG

whether intraoperative dexmedetomidine was administered adjunct to propofol for patients undergoing surgeries under general anaesthesia

dexmedetomidine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All adult patients (aged ≥18 years) admitted for surgical procedures under general anaesthesia with propofol at the five participating hospitals from January 1, 2014 to June 30, 2018.

You may qualify if:

• adult patients (aged ≥18 years)
• undergo general anaesthesia with propofol
• from January 1, 2014 to June 30, 2018

You may not qualify if:

• patients undergoing intervention procedures under monitored anaesthesia care (MAC)
• patients undergoing minor procedures under local or regional anaesthesia

Sponsors & Collaborators

• Xijing Hospital: lead
• The Affiliated Hospital of Qingdao University: collaborator
• First Hospital of China Medical University: collaborator
• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School: collaborator
• Sir Run Run Shaw Hospital: collaborator

MeSH Terms

Interventions

Dexmedetomidine

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: January 24, 2024
• First Posted: February 8, 2024
• Study Start: September 1, 2014
• Primary Completion: June 30, 2018
• Study Completion: July 1, 2018
• Last Updated: February 8, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share